{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:33:34Z","timestamp":1782977614394,"version":"3.54.5"},"reference-count":81,"publisher":"Portland Press Ltd.","issue":"7","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Parkinson's disease (PD) and related neurodegenerative disorders, termed the synucleinopathies, are characterized pathologically by the accumulation of protein aggregates containing \u03b1-synuclein (aSyn), resulting in progressive neuronal loss. There is considerable need for the development of neuroprotective strategies to halt or slow disease progression in these disorders. To this end, evaluation of genetic mutations associated with the synucleinopathies has helped to elucidate crucial mechanisms of disease pathogenesis, revealing key roles for lysosomal and mitochondrial dysfunction. The GBA1 gene, which encodes the lysosomal hydrolase \u03b2-glucocerebrosidase (GCase) is the most common genetic risk factor for PD and is also linked to other neurodegenerative disorders including dementia with Lewy bodies (DLB). Additionally, homozygous mutations in GBA1 are associated with the rare lysosomal storage disorder, Gaucher's disease (GD). In this review, we discuss the current knowledge in the field regarding the diverse roles of GCase in neurons and the multifactorial effects of loss of GCase enzymatic activity. Importantly, GCase has been shown to have a bidirectional relationship with aSyn, resulting in a pathogenic feedback loop that can lead to progressive aSyn accumulation. Alterations in GCase activity have furthermore been linked to multiple distinct pathways involved in neurodegeneration, and therefore GCase has emerged as a promising target for therapeutic drug development for PD and related neurodegenerative disorders, particularly DLB.<\/jats:p>","DOI":"10.1042\/ebc20210018","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T11:39:37Z","timestamp":1631792377000},"page":"873-883","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Glucocerebrosidase dysfunction in neurodegenerative disease"],"prefix":"10.1042","volume":"65","author":[{"given":"Sarah\u00a0M.","family":"Brooker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-1886","authenticated-orcid":false,"given":"Dimitri","family":"Krainc","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"2021122211020704000_B1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1474-4422(18)30355-7","article-title":"The burden of Parkinson's disease: a worldwide perspective","volume":"17","author":"Rocca","year":"2018","journal-title":"Lancet Neurol."},{"key":"2021122211020704000_B2","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"2021122211020704000_B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","article-title":"Glucocerebrosidase and its relevance to Parkinson disease","volume":"14","author":"Do","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"2021122211020704000_B4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2021122211020704000_B5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"2021122211020704000_B6","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"2021122211020704000_B7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"2021122211020704000_B8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","article-title":"Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture","volume":"53","author":"Chia","year":"2021","journal-title":"Nat. Genet."},{"key":"2021122211020704000_B9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","article-title":"Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol."},{"key":"2021122211020704000_B10","doi-asserted-by":"publisher","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","article-title":"alpha-Synuclein pathology in Parkinson's disease and related alpha-synucleinopathies","volume":"709","author":"Henderson","year":"2019","journal-title":"Neurosci. Lett."},{"key":"2021122211020704000_B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"2021122211020704000_B12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"2021122211020704000_B13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","article-title":"Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?","volume":"79","author":"Tayebi","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"2021122211020704000_B14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"2021122211020704000_B15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J. Med. Genet."},{"key":"2021122211020704000_B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139","author":"Migdalska-Richards","year":"2016","journal-title":"J. Neurochem."},{"key":"2021122211020704000_B17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/mds.25248","article-title":"The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease","volume":"28","author":"Duran","year":"2013","journal-title":"Mov. Disord."},{"key":"2021122211020704000_B18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","article-title":"Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers","volume":"78","author":"Anheim","year":"2012","journal-title":"Neurology"},{"key":"2021122211020704000_B19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","article-title":"Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson's disease","volume":"91","author":"Stoker","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2021122211020704000_B20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","article-title":"Molecular mechanisms of alpha-synuclein and GBA1 in Parkinson's disease","volume":"373","author":"Stojkovska","year":"2018","journal-title":"Cell Tissue Res."},{"key":"2021122211020704000_B21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER stress and autophagic perturbations lead to elevated extracellular alpha-synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"2021122211020704000_B22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"key":"2021122211020704000_B23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mds.25349","article-title":"The role of SCARB2 as susceptibility factor in Parkinson's disease","volume":"28","author":"Hopfner","year":"2013","journal-title":"Mov. Disord."},{"key":"2021122211020704000_B24","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1073\/pnas.88.23.10544","article-title":"Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state","volume":"88","author":"Beutler","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122211020704000_B25","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mdc3.12481","article-title":"Frequency of GBA variants in autopsy-proven multiple system atrophy","volume":"4","author":"Sklerov","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"2021122211020704000_B26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"2021122211020704000_B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"2021122211020704000_B28","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122211020704000_B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","article-title":"Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels","volume":"121","author":"Gundner","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"2021122211020704000_B30","doi-asserted-by":"publisher","first-page":"92.e10","DOI":"10.1016\/j.neuron.2017.12.012","article-title":"Reversible conformational conversion of alpha-synuclein into toxic assemblies by glucosylceramide","volume":"97","author":"Zunke","year":"2018","journal-title":"Neuron"},{"key":"2021122211020704000_B31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.1700465115","article-title":"GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122211020704000_B32","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson's disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J. Neurosci."},{"key":"2021122211020704000_B33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.1245296","article-title":"Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons","volume":"342","author":"Chung","year":"2013","journal-title":"Science"},{"key":"2021122211020704000_B34","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.1520335113","article-title":"alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models","volume":"113","author":"Mazzulli","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122211020704000_B35","doi-asserted-by":"publisher","first-page":"869.e11","DOI":"10.1016\/j.neuron.2019.09.001","article-title":"Stress-induced cellular clearance is mediated by the SNARE protein ykt6 and disrupted by alpha-synuclein","volume":"104","author":"Cuddy","year":"2019","journal-title":"Neuron"},{"key":"2021122211020704000_B36","doi-asserted-by":"publisher","first-page":"28080","DOI":"10.1074\/jbc.M111.237859","article-title":"Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases","volume":"286","author":"Yap","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2021122211020704000_B37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ymgme.2012.11.010","article-title":"Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity","volume":"108","author":"Yap","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"2021122211020704000_B38","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"2021122211020704000_B39","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"key":"2021122211020704000_B40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"2021122211020704000_B41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1126\/science.aam9080","article-title":"Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease","volume":"357","author":"Burbulla","year":"2017","journal-title":"Science"},{"key":"2021122211020704000_B42","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"key":"2021122211020704000_B43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","article-title":"Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease","volume":"155","author":"Zucca","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"2021122211020704000_B44","doi-asserted-by":"publisher","first-page":"13621","DOI":"10.1074\/jbc.M109.074617","article-title":"Lysosomal degradation of alpha-synuclein in vivo","volume":"285","author":"Mak","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2021122211020704000_B45","first-page":"777","article-title":"Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy","volume":"118","author":"Martinez-Vicente","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2021122211020704000_B46","doi-asserted-by":"publisher","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122211020704000_B47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.parkreldis.2018.12.014","article-title":"Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: risk estimates and genotype-phenotype correlations","volume":"62","author":"Yahalom","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"2021122211020704000_B48","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/mds.28066","article-title":"A possible modifying effect of the G2019S mutation in the LRRK2 gene on GBA Parkinson's disease","volume":"35","author":"Omer","year":"2020","journal-title":"Mov. Disord."},{"key":"2021122211020704000_B49","doi-asserted-by":"publisher","first-page":"e215845","DOI":"10.1001\/jamanetworkopen.2021.5845","article-title":"Association of dual LRRK2 G2019S and GBA variations with Parkinson disease progression","volume":"4","author":"Ortega","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"2021122211020704000_B50","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-019-13413-w","article-title":"LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients","volume":"10","author":"Ysselstein","year":"2019","journal-title":"Nat. Commun."},{"key":"2021122211020704000_B51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrm2728","article-title":"Rab GTPases as coordinators of vesicle traffic","volume":"10","author":"Stenmark","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021122211020704000_B52","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3389\/fnins.2020.00442","article-title":"LRRK2 kinase inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-derived neurons","volume":"14","author":"Sanyal","year":"2020","journal-title":"Front. Neurosci."},{"key":"2021122211020704000_B53","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/mds.27994","article-title":"Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition","volume":"35","author":"Sanyal","year":"2020","journal-title":"Mov. Disord."},{"key":"2021122211020704000_B54","first-page":"90","article-title":"Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients","volume":"2","author":"Doorn","year":"2014","journal-title":"Acta. Neuropathol. Commun."},{"key":"2021122211020704000_B55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","article-title":"Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction","volume":"111","author":"Ginns","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"2021122211020704000_B56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nbd.2018.12.001","article-title":"Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity","volume":"124","author":"Mus","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"2021122211020704000_B57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2015.6307","article-title":"Sustained systemic glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement C1q activation in mice","volume":"23","author":"Rocha","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"2021122211020704000_B58","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2174\/138620708786734244","article-title":"Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening","volume":"11","author":"Urban","year":"2008","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"2021122211020704000_B59","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1182\/blood.V89.9.3412","article-title":"Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity","volume":"89","author":"Lorincz","year":"1997","journal-title":"Blood"},{"key":"2021122211020704000_B60","doi-asserted-by":"publisher","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","article-title":"Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease","volume":"8","author":"Atashrazm","year":"2018","journal-title":"Sci. Rep."},{"key":"2021122211020704000_B61","doi-asserted-by":"publisher","first-page":"e104862","DOI":"10.15252\/embj.2020104862","article-title":"LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes","volume":"39","author":"Liu","year":"2020","journal-title":"EMBO J."},{"key":"2021122211020704000_B62","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease\u2013links to Parkinson's disease","volume":"17","author":"Osellame","year":"2013","journal-title":"Cell Metab."},{"key":"2021122211020704000_B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","article-title":"alpha-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism","volume":"13","author":"Yun","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"2021122211020704000_B64","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Schondorf","year":"2014","journal-title":"Nat. Commun."},{"key":"2021122211020704000_B65","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41418-019-0442-2","article-title":"Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload","volume":"27","author":"Plotegher","year":"2020","journal-title":"Cell Death Differ."},{"key":"2021122211020704000_B66","doi-asserted-by":"publisher","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","article-title":"Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease","volume":"288","author":"Surmeier","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2021122211020704000_B67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"2021122211020704000_B68","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature25486","article-title":"Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis","volume":"554","author":"Wong","year":"2018","journal-title":"Nature"},{"key":"2021122211020704000_B69","doi-asserted-by":"publisher","first-page":"339.e4","DOI":"10.1016\/j.devcel.2019.05.033","article-title":"Lysosomal regulation of inter-mitochondrial contact fate and motility in Charcot-Marie-Tooth Type 2","volume":"50","author":"Wong","year":"2019","journal-title":"Dev. Cell"},{"key":"2021122211020704000_B70","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41467-021-22113-3","article-title":"Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"2021122211020704000_B71","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"2021122211020704000_B72","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"2021122211020704000_B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.12.298","article-title":"Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a\u202fGBA\u202fmutation","volume":"126","author":"Peterschmitt","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"2021122211020704000_B74","doi-asserted-by":"publisher","first-page":"eaau6870","DOI":"10.1126\/scitranslmed.aau6870","article-title":"A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease","volume":"11","author":"Burbulla","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"2021122211020704000_B75","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2021122211020704000_B76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"2021122211020704000_B77","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with gaucher disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"2021122211020704000_B78","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of beta-glucocerebrosidase reduces pathological alpha-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci."},{"key":"2021122211020704000_B79","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."},{"key":"2021122211020704000_B80","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","article-title":"Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons","volume":"82","author":"Rocha","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"2021122211020704000_B81","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212739","article-title":"Gene therapy for Parkinson's disease associated with GBA1 mutations","author":"Abeliovich","year":"2021","journal-title":"J. Parkinsons Dis."}],"container-title":["Essays in Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/65\/7\/873\/926960\/ebc-2021-0018c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/65\/7\/873\/926960\/ebc-2021-0018c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T11:43:49Z","timestamp":1640173429000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article\/65\/7\/873\/229792\/Glucocerebrosidase-dysfunction-in"}},"subtitle":[],"editor":[{"given":"Glenda","family":"Halliday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Nicolas","family":"Dzamko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":81,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,12,22]]},"published-print":{"date-parts":[[2021,12,22]]}},"URL":"https:\/\/doi.org\/10.1042\/ebc20210018","relation":{},"ISSN":["0071-1365","1744-1358"],"issn-type":[{"value":"0071-1365","type":"print"},{"value":"1744-1358","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,12]]}}}